Literature DB >> 22484425

MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.

J H Schulte1, S Lindner, A Bohrer, J Maurer, K De Preter, S Lefever, L Heukamp, S Schulte, J Molenaar, R Versteeg, T Thor, A Künkele, J Vandesompele, F Speleman, H Schorle, A Eggert, A Schramm.   

Abstract

Neuroblastoma is an embryonal tumor with a heterogeneous clinical course. The tumor is presumed to be derived from the neural crest, but the cells of origin remain to be determined. To date, few recurrent genetic changes contributing to neuroblastoma formation, such as amplification of the MYCN oncogene and activating mutations of the ALK oncogene, have been identified. The possibility to model neuroblastoma in mice allows investigation of the cell of origin hypothesis in further detail. Here we present the evidence that murine neural crest progenitor cells can give rise to neuroblastoma upon transformation with MYCN or ALK(F1174L). For this purpose we used JoMa1, a multipotent neural crest progenitor cell line, which is kept in a viable and undifferentiated state by a tamoxifen-activated c-Myc transgene (c-MycER(T)). Expression of MYCN or ALK(F1174L), one of the oncogenic ALK variants identified in primary neuroblastomas, enabled these cells to grow independently of c-MycER(T) activity in vitro and caused formation of neuroblastoma-like tumors in vivo in contrast to parental JoMa1 cells and JoMa1 cells-expressing TrkA or GFP. Tumorigenicity was enhanced upon serial transplantation of tumor-derived cells, and tumor cells remained susceptible to the MYC-inhibitor, NBT-272, indicating that cell growth depended on functional MYCN. Our findings support neural crest progenitor cells as the precursor cells of neuroblastoma, and indicate that neuroblastomas arise as their malignant progeny.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484425     DOI: 10.1038/onc.2012.106

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma.

Authors:  Alina Naveed; Jack A Cooper; Ruohan Li; Alysia Hubbard; Jingwei Chen; Tao Liu; Steve D Wilton; Sue Fletcher; Archa H Fox
Journal:  Cell Mol Life Sci       Date:  2020-09-10       Impact factor: 9.261

2.  Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.

Authors:  Mengling Liu; Yingfeng Xia; Jane Ding; Bingwei Ye; Erhu Zhao; Jeong-Hyeon Choi; Ahmet Alptekin; Chunhong Yan; Zheng Dong; Shuang Huang; Liqun Yang; Hongjuan Cui; Yunhong Zha; Han-Fei Ding
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

3.  Cell-based methods for the identification of MYC-inhibitory small molecules.

Authors:  Catherine A Burkhart; Michelle Haber; Murray D Norris; Andrei V Gudkov; Mikhail A Nikiforov
Journal:  Methods Mol Biol       Date:  2013

Review 4.  Neuroblastoma: molecular pathogenesis and therapy.

Authors:  Chrystal U Louis; Jason M Shohet
Journal:  Annu Rev Med       Date:  2014-10-27       Impact factor: 13.739

5.  CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.

Authors:  C Delehouzé; K Godl; N Loaëc; C Bruyère; N Desban; N Oumata; H Galons; T I Roumeliotis; E G Giannopoulou; J Grenet; D Twitchell; J Lahti; N Mouchet; M-D Galibert; S D Garbis; L Meijer
Journal:  Oncogene       Date:  2013-12-09       Impact factor: 9.867

Review 6.  Origin and initiation mechanisms of neuroblastoma.

Authors:  Shoma Tsubota; Kenji Kadomatsu
Journal:  Cell Tissue Res       Date:  2018-02-14       Impact factor: 5.249

7.  The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.

Authors:  Bin Yi; Jixin Yang; Lizhong Wang
Journal:  Tumour Biol       Date:  2013-11-30

8.  Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma.

Authors:  Gabriele Büchel; Johannes H Schulte; Luke Harrison; Katharina Batzke; Ulrich Schüller; Wiebke Hansen; Alexander Schramm
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

9.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

Review 10.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.